Trial Profile
Randomized Open-Label Trial to Compare Immunogenicity of Egg-Based and Non-Egg Based Quadrivalent Influenza Vaccines Among Adults 18-64 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2018-19 and 2019-20)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; GSK 2282512A
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Acronyms RIVER
- 21 Apr 2023 Planned End Date changed from 30 Sep 2022 to 30 Dec 2023.
- 02 May 2022 Planned End Date changed from 31 Jan 2022 to 30 Sep 2022.
- 16 Nov 2021 Planned End Date changed from 1 Sep 2020 to 31 Jan 2022.